Semaglutide denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Semaglutide as Duplicate Therapy

A duplicate-therapy denial from UnitedHealthcare (UHC) means the plan's clinical review concluded that the patient is already receiving a drug it considers therapeutically equivalent or overlapping — often another GLP-1 receptor agonist or a drug in the same class used for the same indication. This can also occur when two prescriptions for similar agents exist on the member's active medication list, even if one was intended to be discontinued.

## Why This Denial Is Appealable

Duplicate-therapy denials frequently rest on automated pharmacy-claim flags rather than a clinical review of why the patient's prescriber chose this specific agent. If the agents are not truly equivalent for this patient — due to differences in formulation, tolerability, route, or indication-specific clinical profile — that distinction is the core of the appeal. Under ACA Section 2719 and ERISA Section 503, you have the right to internal appeal and independent external review. The external-review window is generally open for approximately four months from the denial notice. Expedited review (typically 72-hour turnaround) is available when the situation is clinically urgent.

## The Appeal Process

1. Identify what UHC flagged as the duplicate — the denial letter should name the drug the plan considers equivalent. 2. Clarify active medication status — if the prior agent is no longer active, have the prescriber document discontinuation with date and reason. 3. File the internal appeal — confirm the deadline from your Explanation of Benefits. 4. Request external review if the internal appeal is denied.

## Documentation to Gather

• Medication reconciliation: a current, dated medication list from the prescriber confirming which agents are and are not active.
• Discontinuation documentation: if the flagged "duplicate" was previously prescribed but stopped, chart notes documenting when it was stopped and why.
• Clinical distinction letter: a prescriber letter explaining why the requested drug is not therapeutically interchangeable with the flagged agent for this specific patient — addressing tolerability, formulation differences, or indication-specific clinical reasoning.
• Diagnosis documentation: chart notes confirming the indication for which semaglutide is being prescribed.

## Criteria-Mapping Structure

Obtain UHC's coverage policy and review the clinical criteria that define "duplicate therapy" for this drug class. For each criterion, provide a direct chart-based response. The most effective appeals in this category combine a clear medication reconciliation showing only one active agent with a prescriber attestation that the drugs are not clinically interchangeable for this patient — eliminating the factual basis for the denial.